TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18568411

Group type: EXPERIMENTAL
Intervention: Single-knot running technique with Lapra-Ty clips
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-knot running technique without Lapra-Ty clips
Number of subjects: 50
Study: 17299480

Group type: EXPERIMENTAL
Intervention: High glycaemic index preload (Ovaltine Light)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low glycaemic index preload (milk)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-nutritive control (water)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 12
Study: 15615349

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-administration of drugs with complementary mechanisms
Number of subjects: 0
Study: 11977649

Group type: EXPERIMENTAL
Intervention: Pre-operative intra-arterial infusion chemotherapy (mitomycin 10 mg, 5-FU 1,000 mg, epirubicin 60 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no pre-operative intra-arterial infusion chemotherapy)
Number of subjects: 28
Study: 9737101

Group type: EXPERIMENTAL
Intervention: TTS fentanyl (25, 50, 75, or 100 micrograms/hr) administered as a transdermal patch every 3 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TTS fentanyl
Number of subjects: 53
Study: 8287749

Group type: COMPARATOR
Intervention: Oral mesalazine (0.5 g three times/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mesalazine enemas (4 g of 5-aminosalicylic acid enema every third night)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral mesalazine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mesalazine enemas
Number of subjects: 38
Study: 2576397

Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.05 mg daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CV 205‐502 (mean 0.09 mg a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CV 205‐502
Number of subjects: 10
Study: 795022

Group type: EXPERIMENTAL
Intervention: 0.50 g a day of penicillamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1 g a day of penicillamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 mg a day of zinc metal supplement with 0.50 g a day of penicillamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 mg a day of zinc metal supplement with 1 g a day of penicillamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo with 0.50 g a day of penicillamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo with 1 g a day of penicillamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo with zinc supplement
Number of subjects: 66
Study: 31977236

Group type: EXPERIMENTAL
Intervention: Pagan spell-casting intervention (Group A: weeks 1-2; Group B: weeks 2-3)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (Group B: delayed intervention)
Number of subjects: 44
Study: 31000844

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lullaby
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 27592680

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (200 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (200 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (800 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination lactoferrin/immunoglobulin (200 mg/200 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination lactoferrin/immunoglobulin (200 mg/800 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25760977

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles with a fixed 3-month interval after the first four courses)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Continuous docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles)
Number of subjects: 148
Study: 22268979

Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment (MBT, n = 12)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive behavioral treatment (CBT, n = 8)
Number of subjects: 20
Study: 20628646

Group type: EXPERIMENTAL
Intervention: Hearing the letter name prior to the detection task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual cue in the form of a preview of the to-be-detected letter
Number of subjects: 0
Study: 18779611

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m(2))
Number of subjects: 489
Study: 16395996

Group type: EXPERIMENTAL
Intervention: Odds Ratio (OR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative Risk (RR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference (DEL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exact Fisher type test for one-sided equivalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian test for non-inferiority
Number of subjects: 0
Study: 12507207

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional techniques
Number of subjects: 0
Study: 10494379

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1.0 g administered intravenously 15 minutes prior to surgery
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 31
Study: 8942008

Group type: EXPERIMENTAL
Intervention: D'Allergen treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated homes)
Number of subjects: 30
Study: 1683593

Group type: EXPERIMENTAL
Intervention: Imaginal desensitisation (ID)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Other behavioural procedures (control)
Number of subjects: 120
Study: 6125483

Group type: EXPERIMENTAL
Intervention: Tofizopam (100 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Tofizopam (100 mg, three times)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30808899

Group type: EXPERIMENTAL
Intervention: real-NMMS (rNMMS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: sham NMMS (sNMMS)
Number of subjects: 22
Study: 29268764

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS and sham PES (group 1; n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sham tDCS and active PES (group 2; n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham tDCS and PES (group 3; n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active tDCS and PES (group 4; n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 80
Study: 25715664

Group type: EXPERIMENTAL
Intervention: Standard dose X-ray examination (0.365 mSv)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Reduced dose X-ray examination (0.211 mSv)
Number of subjects: 289
Study: 24515928

Group type: EXPERIMENTAL
Intervention: Community-based exercise program with telerehabilitation monitoring; practice at least twice a week at the kiosk and at least 3 more days a week at home.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23027657

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.5 mg lorazepam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19653743

Group type: EXPERIMENTAL
Intervention: Temporal masking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous masking
Number of subjects: 0
Study: 17723159

Group type: EXPERIMENTAL
Intervention: Herbal medicinal product containing Tropaeoli majoris herba and Armoraciae rusticanae radix, administered twice daily for 90 days.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 90 days.
Number of subjects: 174
Study: 16469334

Group type: EXPERIMENTAL
Intervention: Checkpoints Program (intervention families received persuasive communications and a parent-teen driving agreement)
Number of subjects: 3743

Group type: COMPARATOR
Intervention: Standard information on driver safety (comparison families)
Number of subjects: 3743
Study: 12720074

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride plus IL-2
Number of subjects: 301

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 301
Study: 10921531

Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 8781825

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg t.i.d.) as adjuvant therapy to standard therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard therapy (thrombolysis, beta-blockers, and nitrates)
Number of subjects: 77
Study: 1464341

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Captopril 25.0 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Captopril low dose group (incremental doses of 6.25, 12.5, and 25.0 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Captopril high dose group (25.0 mg 8 hourly)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Captopril (both doses)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 41
Study: 6099135

Group type: EXPERIMENTAL
Intervention: Alpha 2-adrenoceptor agonist alpha-methylnoradrenaline (MNA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin II (A II)
Number of subjects: 0
Study: 30528770

Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (MOIT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IgE-binding epitopes
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Optimum model using 6 IgE-binding epitopes
Number of subjects: 55
Study: 28429912

Group type: EXPERIMENTAL
Intervention: Cow or goat milk-based infant formulae (combined groups)
Number of subjects: 180
Study: 25567231

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² for in vivo purging 3-5 days pre-stem cell collection and 2×4 weekly at 2 and 6 months post-ASCT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rituximab (three infusions pre-stem cell collection followed by 6× R weekly and interferon-α 3 MU/m² SC TIW)
Number of subjects: 73

Group type: COMPARATOR
Intervention: High-dose therapy and autologous stem cell transplantation (HDT/ASCT) without rituximab
Number of subjects: 73
Study: 25362822

Group type: EXPERIMENTAL
Intervention: 1 g of omega-3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 g of omega-3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (vitamin E 200 IU)
Number of subjects: 60
Study: 20434293

Group type: EXPERIMENTAL
Intervention: Telephone-based supportive intervention for parents of young children with T1D
Number of subjects: 24
Study: 19745745

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1263

Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 1263
Study: 17404792

Group type: EXPERIMENTAL
Intervention: E-PEG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pull-method PEG
Number of subjects: 30
Study: 14960741

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide group
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 452
Study: 11307124

Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study: 9399309

Group type: EXPERIMENTAL
Intervention: Computer-aided cognitive rehabilitation (six 1-hr sessions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Graphics-based computer games (six sessions)
Number of subjects: 10
Study: 7962339

Group type: COMPARATOR
Intervention: Isoproterenol (dose required to increase resting heart rate by 25 beats/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose (75 g) administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Symptoms after glucose intake
Number of subjects: 8

Group type: COMPARATOR
Intervention: SCL-90R questionnaire
Number of subjects: 8
Study: 2894081

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily for three days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg three hours before challenge
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of flurbiprofen and terfenadine
Number of subjects: 14
Study: 31866308

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg 3 x daily for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (3 x daily for 10 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Withdrawal (150 mg caffeine 3 x daily for eight days, followed by placebo for two days)
Number of subjects: 20
Study: 30484824

Group type: EXPERIMENTAL
Intervention: Interval appendectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Follow-up with magnetic resonance imaging
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29231430

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) for 30 min before and after embryo transfer, applied on specific acupoints.
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Control group (no TEAS).
Number of subjects: 1761
Study: 26112723

Group type: EXPERIMENTAL
Intervention: POTTS-E group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 23772581

Group type: EXPERIMENTAL
Intervention: Medical and rehabilitation treatment (Group 1)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Medical treatment (Group 2)
Number of subjects: 390
Study: 22115059

Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record (IPHR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IPHR
Number of subjects: 14
Study: 19502748

Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid (DGLA)-enriched oil (50 or 150 mg as free DGLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid (DGLA)-enriched oil
Number of subjects: 0
Study: 17035557

Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 121

Group type: COMPARATOR
Intervention: Clubhouse
Number of subjects: 121
Study: 15525889

Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemo Embolization (TACE)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Percutaneous Ethanol Injection (PEI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Laser Thermal Ablation (LTA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 89
Study: 12727079

Group type: EXPERIMENTAL
Intervention: Ceftriaxone with dexamethasone (group 1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceftriaxone alone (group 2)
Number of subjects: 12
Study: 10962414

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 1040
Study: 8796773

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous bolus of ephedrine (10 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (no prophylactic ephedrine)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Among newborns of hypotensive mothers (ephedrine group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Among newborns of hypotensive mothers (control group)
Number of subjects: 122
Study: 1519607

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (drug therapy)
Number of subjects: 32
Study: 6322710

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nystatin (500,000 units four times daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 36
Study: 30776384

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrathin Descemet stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 0
Study: 30523434

Group type: EXPERIMENTAL
Intervention: Tumor genetic profiling (NGS implementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not receiving tumor genetic profiling (control group)
Number of subjects: 0
Study: 27098427

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 18

Group type: COMPARATOR
Intervention: Axitinib plus lomustine
Number of subjects: 18
Study: 24361207

Group type: EXPERIMENTAL
Intervention: Physical Exercise Program (PEP); 8-week training program, once a week, including warm-up exercises, muscle strengthening, stretching, balancing, and self-administered massage to acupressure points.
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (no PEP);
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Physical Exercise Program (PEP);
Number of subjects: 396
Study: 22149546

Group type: COMPARATOR
Intervention: hsCRP in subjects with NAFLD (4.2±1.2 mg/L)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Leukocyte count in subjects with NAFLD (7.8±1.4×10(3)/μL)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Leukocyte count
Number of subjects: 200
Study: 20223100

Group type: EXPERIMENTAL
Intervention: Ingestion of nonalcoholic wine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Use of mouthwash
Number of subjects: 12
Study: 18566924

Group type: EXPERIMENTAL
Intervention: Physical activity counseling program (30 min walking 5 days a week and 15 min lower-limb strength training 3 days a week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 15684252

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (age-matched subjects)
Number of subjects: 30
Study: 11934200

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 15
Study: 10444055

Group type: EXPERIMENTAL
Intervention: Aspheric multifocal back surface RGP contact lens
Number of subjects: 28
Study: 7576895

Group type: EXPERIMENTAL
Intervention: Selenium supplemented formula (17 micrograms Se/L)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unsupplemented formula (4.6 micrograms Se/L)
Number of subjects: 44
Study: 2156764

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon cream (IFN) - 9 x 10(6) IU applied deep into the vagina every night for 2-week courses 1 week apart, for a total treatment period of 12 months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 372222

Group type: EXPERIMENTAL
Intervention: Oxi/Ferm identification system
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional test battery
Number of subjects: 96
Study: 30860009

Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Soap (control)
Number of subjects: 32
Study: 28616651

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP block)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Iliohypogastric/ilioinguinal nerve block (IHINB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 90
Study: 25052844

Group type: EXPERIMENTAL
Intervention: iTrainer (iT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Pelvic Trainer (SPT)
Number of subjects: 45
Study: 23776033

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 14 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21562449

Group type: EXPERIMENTAL
Intervention: Tacrolimus (mean level 7.2 ± 2.54 ng/mL)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (mean dose 1.5 ± 0.61 g/day)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Other variables (acute rejection, donor age, delayed graft function)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Stage II CKD (60‐89 mL/min) and Stage III CKD (30‐59 mL/min)
Number of subjects: 998
Study: 19501034

Group type: EXPERIMENTAL
Intervention: Self-management educational program (6 months, 5 components: background, medication, physical exercise, nutrition, blood glucose self-monitoring)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Self-management educational program (6 months)
Number of subjects: 25
Study: 16490760

Group type: EXPERIMENTAL
Intervention: Magnesium gluconate (i.v. bolus of 0.21 mmol kg(‐1) followed by a continuous infusion of 0.03 mmol(‐1) kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15311667

Group type: EXPERIMENTAL
Intervention: Object file continuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervening stream items between T1 and T2
Number of subjects: 0
Study: 11369255

Group type: EXPERIMENTAL
Intervention: Surgery during the menstrual cycle phase with ovulation
Number of subjects: 0
Study: 9549961

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 56
Study: 7839784

Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 of racemic ketamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 of S‐(+) ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1 mg.kg‐1 of midazolam (prior administration)
Number of subjects: 50
Study: 3277779

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg boluses every 6 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (125 micrograms/kg.h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (250 micrograms/kg.h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1464545

Group type: EXPERIMENTAL
Intervention: Zoladex (depot injection every 28 days)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Zoladex plus flutamide (3 x 250 mg tablets daily)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 589

Group type: COMPARATOR
Intervention: Zoladex plus flutamide
Number of subjects: 589
Study: 889333

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.1% cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salicylic acid 2% cream
Number of subjects: 40